
European Early-Stage Capital Spreads Across Biotech and AI Deeptech
Fresh rounds from Vienna, Stockholm and a speech-AI player point to deep-tech investor appetite — and platforms built to scale into emerging markets.

Thabo Nkosi
Southern Africa Editor · Johannesburg
A cluster of early-stage European deals this week underlines where investors are placing their bets in 2026: precision biology, industrial AI and speech technology built to cross borders. For founders and capital flowing between Europe and Africa, the common thread is platform-based companies designed to scale across multiple markets rather than a single domestic base.
Vienna biotech bets on epigenome editing
Epitome Therapeutics, a Vienna-based spin-off from the European Molecular Biology Laboratory (EMBL), announced €4 million in total funding, EU-Startups reported. The package combines an oversubscribed €2 million pre-seed round with €2 million in non-dilutive grants, co-led by XISTA Science Ventures and Caesar Ventures, with Navec Venture Holding also participating.
Keep reading
Common Path Launches to Open UK Startups to Low-Income Graduates
A coalition of social mobility and venture capital names has launched Common Path to place graduates from low-income backgrounds into UK startup roles.
One newsletter, two continents
The Bridge brings you the tech, startups, and leaders moving between Africa and Europe — one sharp email each morning. No spam, unsubscribe anytime.








